Telegram RegisterThe public register of Telegram
Telegram profile photo for Dr Ana Naderi

Channel

Dr Ana Naderi

@drAnaNaderi

On this record: Growth · Engagement · Reactions · Posts · Citations · Cite this entry

821subscribers

-6 since we began measuring on 13 August 2026

Risers and fallers across the register · movement among entries of Under 1,000.

Register entry

Telegram ID-1001879384664
TypeChannel
Username@drAnaNaderi
CreatedBetween 1 October 2022 and 30 September 2023 — estimated from Telegram’s id allocation, not measured. How this range is calculated.
First recorded13 August 2026
Last confirmed live4 September 2026
Measurements held5
Confirmed unchanged1 time, most recently 4 September 2026
On Telegramt.me/drAnaNaderi

Growth

82182782413 August 2026 — 827 subscribers13 August 2026 — 827 subscribers20 August 2026 — 824 subscribers27 August 2026 — 822 subscribers4 September 2026 — 821 subscribers13 August 20264 September 2026
5 measurements spanning 22 days, net -6. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 820–828 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
4 Sept 2026, 01:57821-1
27 Aug 2026, 16:46822-2
20 Aug 2026, 09:11824-3
13 Aug 2026, 17:29827no change
13 Aug 2026, 06:04827first reading

Engagement

20 posts held, back to 6 September 2025the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 1 page of Telegram’s post history, 20 posts per page.

Nothing published in the last 30 days. ERR and ER are rolling 30-day measures, so there is nothing to compute — we hold 20 posts for this entry, the most recent from 31 May 2026. An engagement rate over an empty window would be a number about nothing.

Reaction mix

139 reactions across 18 posts, in 7 distinct kinds. The most used accounts for 70.5% of them.

Every reaction kind recorded on the sample, most used first
ReactionCountShareShare, drawn
9870.5%
👏117.91%
👍107.19%
💯64.32%
🙏64.32%
👌53.60%
😢32.16%

No sentiment is inferred, and none should be read in. This table is ordered by count and by nothing else. Emoji do not carry stable meaning across languages or communities — 🙏 is thanks in one channel and mourning in another — so we publish which ones were pressed and how often, and pass no judgement on what an audience meant by them.

Precision. Telegram publishes reaction counts per emoji and short-forms each one — 4.34K, 1.2M — so any single kind at or above 1,000 reaches us at three significant figures, and only counts below 1,000 are exact. The shares above are ratios of those figures and carry the same error. This is also why the total here can differ slightly from a reaction total printed elsewhere on the page: both are sums of the same rounded parts, taken over samples with different edges.

Coverage. Reactions were read on 18 of the 20 sampled posts in this sample. Summed by Telegram’s own count on each post — not by adding up the per-emoji breakdown above — those same posts carry 139 reactions in total: the kind of figure the paragraph above means by “a reaction total printed elsewhere on the page”.

Measured over the 20 most recent posts we hold, published 6 September 2025 to 31 May 2026, using the newest reading held for each. Telegram Stars are excluded: they are a payment, not a reaction, and they have their own section.

Recent posts

31 May 2026, 14:33 UTC393 views17 reactionsread 13 August 2026

🚨خبر مهم در درمان هپاتیت ب مزمن 💡در دو مطالعه بزرگ فاز ۳ که در NEJM منتشر شده‌اند، داروی جدید بپیروویرسن توانست در حدود ۱۹ تا ۲۰ درصد از بیماران منتخب مبتلا به هپاتیت ب مزمن، به «درمان عملکردی» منجر شود؛ یعنی پس از قطع درمان، آنتی‌ژن سطحی هپاتیت ب منفی شد و DNA ویروس نیز سرکوب‌شده باقی ماند. 🔬این مطالعات روی بیماران غیرسیروتیک انجام شده که پیش‌تر تحت درمان پایدار با داروهای ضدویروس مانند تنوفوویر یا انتکاویر بودند

12👍5

31 May 2026, 14:30 UTC356 views2 reactionsread 13 August 2026

https://www.nejm.org/doi/full/10.1056/NEJMoa2515131 🦠🦠🦠🦠🦠🦠🦠 📣بپیروویرسن و آینده درمان هپاتیت ب مزمن یک‌پنجم بیماران، بدون آنتی‌ژن سطحی؛ نقطه عطفی در درمان هپاتیت ب پایانی احتمالی بر درمان مادام‌العمر هپاتیت ب 🌿🌿🌿🌿🌿🌿🌿 https://t.me/drAnaNaderi

2

15 May 2026, 09:35 UTC≈1,520 views8 reactionsread 13 August 2026
Photo

🌵سوالات شایع در مورد هانتا ویروس . . .https://t.me/drAnaNaderi

8

14 May 2026, 11:25 UTC488 views8 reactionsread 13 August 2026
File

هانتا ویروس آپتودیت ۲۰۲۶ 🌿🌿🌿🌿🌿🌿 https://t.me/drAnaNaderi

8

14 May 2026, 09:44 UTC488 views8 reactionsread 13 August 2026
File

آخرین آپدیت هانتا ویروس CDC .MAY 2026 🌿🌿🌿🌿🌿 https://t.me/drAnaNaderi

8

14 May 2026, 09:32 UTC459 views7 reactionsread 13 August 2026
File

هفتمین شماره گزارش هفتگی تهدیدات بهداشتی جهان منتشر گردید: آخرین وضعیت بیماری هانتاویروس تهیه شده توسط مرکز تحقیقات بیماری های نوپدید و بازپدید انستیتو پاستور ایران با همکاری مرکز مدیریت بیماری های واگیر وزارت بهداشت 🌿🌿🌿🌿🌿🌿🌿 https://t.me/drAnaNaderi

7

5 Dec 2025, 08:37 UTC991 views9 reactionsread 13 August 2026

👾در این مقاله با عنوان «World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults» به توضیح رهنمود جدید سازمان جهانی بهداشت (WHO) درباره استفاده از داروهایی با مکانیسم GLP-1 برای درمان چاقی در بزرگسالان پرداخته شده است. 🤡چاقی را به‌عنوان یک بیماری مزمن و عودکننده تلقی کرده که نیاز به مراقبت بلندمدت دارد — شامل تشخیص زودهنگام، بررسی عوا

9

5 Dec 2025, 08:26 UTC722 viewsread 13 August 2026

https://jamanetwork.com/journals/jama/fullarticle/2842199?guestAccessKey=c54b0a37-ccd5-4ecc-b541-764413e030c5&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=120125&fbclid=PARlRTSAObnIBleHRuA2FlbQIxMQBzcnRjBmFwcF9pZA8xMjQwMjQ1NzQyODc0MTQAAacWHCwsaoBWRDOiqslCMfQpfQr748jQtXukMydUCFcUBFRvgzMO1CBYa36jxg_aem_SNX-M10Dd1H0s24MXazMcw 🚩🚩🚩🚩🚩🚩 World Health Organization اولین گاید

19 Nov 2025, 09:22 UTC944 views9 reactionsread 13 August 2026

داده‌های واقعی از کشورهای مختلف که سال‌هاست برنامه واکسیناسیون HPV را اجرا کرده‌اند، نشان می‌دهد این واکسن‌ها به‌طور قابل‌توجهی بروز سرطان دهانهٔ رحم و ضایعات پیش‌سرطانی را کاهش داده‌اند؛ به‌ویژه وقتی واکسیناسیون قبل از ۱۷ سالگی انجام شود. 🔹 اسکاتلند • در زنانی که در سن ۱۲–۱۳ سال واکسن گرفته‌اند، هیچ موردی از سرطان دهانهٔ رحم در پیگیری ۸ تا ۱۲ ساله دیده نشده. 🔹 انگلستان • ۸۷٪ کاهش سرطان دهانهٔ رحم در زنانی که در

6👍3

19 Nov 2025, 09:21 UTC761 views4 reactionsread 13 August 2026

https://www.gavi.org/vaccineswork/hpv-vaccine-erasing-cancer-heres-proof آمار های این مقاله در مورد کاهش سرطان دهانه رحم به دنبال تزریق واکسن HPV خیره کننده است📈 🌿🌿🌿🌿🌿🌿🌿🌿🌿 https://t.me/drAnaNaderi

4

9 Nov 2025, 14:49 UTC≈1,030 views10 reactionsread 13 August 2026
File

مقاومت میکروبی و تجویز منطقی آنتی بیوتیک 🌿🌿🌿🌿🌿🌿 https://t.me/drAnaNaderi

10

5 Nov 2025, 12:33 UTC709 views12 reactionsread 13 August 2026

زمان‌بندی واکسن Influenza در بیماران ایمونوکمپرومایز (IDSA 2025) پیوند عضو جامد (Solid Organ Transplant) • حداقل ۲ هفته قبل از پیوند یا • بیش از ۳ ماه بعد از پیوند • اگر فصل آنفلوآنزا شروع شده → زودتر هم قابل انجام است ⸻ بدخیمی‌های هماتولوژیک • زمان ایده‌آل: حداقل ۲ هفته قبل از شروع درمان • و حداقل ۳ ماه بعد از آخرین دوز درمان • اگر درمان B-cell depleting (مثل Rituximab): • ۳ تا ۶ ماه بعد از آخرین دوز ارجح

12

Showing the 12 most recent of 20 posts we hold for @drAnaNaderi. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Forward network

Republished by

Channels on the register that have forwarded this channel's posts into their own feed.

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 1 registered channel — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

Named by

Channels on the register whose posts name this channel's handle.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 4 September 2026 — this entry's latest reading, not the date you are reading this.

“Dr Ana Naderi” (@drAnaNaderi), 821 subscribers as measured 4 September 2026. Telegram Register, tgregister.com/channel/drAnaNaderi.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.